Thetford Mines, Quebec – June 18, 2026 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the results of an independent evaluation of its digital platform Medherize, conducted by the Breast Disease Centre of CHU de Québec – Université Laval (Hôpital du Saint-Sacrement). Carried out among 243 patients with breast cancer on targeted oral therapies (CDK4/6 inhibitors) between September 2025 and March 2026, the evaluation demonstrates measurable benefits, for both patients and care teams.
Learn more